Tamoxifen-induced non-alcoholic steatohepatitis: Where are we now and where are we going?

Expert Opinion on Drug Safety

Volumn 6, Issue 1, 2007, Pages 1-4

  Osman, Khalid A ^a   Osman, Meissa M ^b   Ahmed, Mohamed H ^c  

^a QUEEN S HOSPITAL   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Non alcoholic steatohepatitis; Tamoxifen

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; AROMATASE INHIBITOR; CHOLESTEROL; ESTROGEN RECEPTOR; EXEMESTANE; EZETIMIBE; GLUCOSE; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; TAMOXIFEN; TRIACYLGLYCEROL;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDITORIAL; EXERCISE; HUMAN; HYPERLIPIDEMIA; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID ANALYSIS; LIVER DISEASE; LIVER FUNCTION; NONALCOHOLIC FATTY LIVER; SCREENING TEST; WEIGHT REDUCTION;

BREAST NEOPLASMS; FATTY LIVER; FEMALE; HEPATITIS, TOXIC; HUMANS; PRACTICE GUIDELINES; TAMOXIFEN;

EID: 33846413204     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.1.1     Document Type: Editorial

References (12)

1. PRATT DS, KNOX TA, ERBAN J: Tamoxifen-induced steatohepatitis. Ann. Intern. Med. (1995) 123(3):236.
2. AHMED MH, BYRNE CD: Non-alcoholic steatoheptatitis. In: Metabolic Syndrome. Byrne CD, Wild S (Eds), Wiley, UK (2005):279-303.
3. GRIECO A, FORGIONE A, MIELE L et al.: Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. (2005) 9(5):261-263.
4. BRUNO S, MAISONNEUVE P, CASTELLANA P et al.: Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ (2005) 330(7497):932.
5. AHMED MH, OSMAN KA: Tamoxifen induced- non-alcoholic steatohepatitis (NASH): has the rime come for the oncologist to be diabetologist. Breast Cancer Res. Treat. (2006)97(2):223-224.
6. OHNISHI T, OGAWA Y, SAIBARA T et al.: CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Hepatol. Res. (2005) 33(2):178-180.
7. PESSAYRE D, FROMENTY B, MANSOURI: Mitochondrial injury in steatohepatitis. Eur. J. Gastroenterol. Hepatol. (2004) 16:1095-1105.
8. COSKUN U, GUNEL N, TORUNER FB et al.: Serum leptin levels are associated with tamoxifen induced hepatic steatosis. Curr. Med. Res. Opin. (2003) 19(1):47-50.
9. AHMED MH, OSMAN KA, OSMAN MM: Invasive and non-invasive investigations for tamoxifen induced-non-alcoholic steatohepatitis (NASH): the benefit of computed tomography scan guided liver biopsy. Pathology (2006) 38(3):270-271.
10. IOANNOU GN, WEISS NS, BOYKO EJ, MOZAFFARIAN D, LEE SP: Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology (2006) 43:1145-1151.
11. AHMED MH, SAAD RA, OSMAN MM: Ezetimibe: is effective and safe treatment for dyslipidaemia associated with non alcoholic fatty liver disease. Expert Opin. Drug Saf. (2006) 5(4):487-488.
12. AHMED MH: Rosuvastatin safe and effective treatment for dyslipidaemia associated with non alcoholic steatohepatitis (NASH). Scand. J. Gastroenterol. (2006) 41(5):613.